Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Multiple Formulations of MK-4082 in Overweight/Obese Participants
NCT07748351Phase 1Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HS-10535 in obesity (4 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experience an Adverse Event at 8 weeks and Number of Participants Who Discontinue Study Treatment Due to an Adverse Event at 6 weeks. Started Aug 2026; status: active, not recruiting.
02
Drugs
HS-10535
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07748351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07748351.